Janux Therapeutics Inc
JANX
查看详细走势图
13.180USD
-0.450-3.30%
收盘 03/27, 16:00（美东）报价延迟15分钟
778.47M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.30%
5天
-6.26%
1月
-3.16%
6月
-43.26%
今年开始到现在
-4.49%
1年
-54.71%
查看详细走势图
TradingKey Janux Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Janux Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名27/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价53.50。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Janux Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Janux Therapeutics Inc亮点
亮点风险
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
业绩高增长
公司营业收入稳步增长，连续3年增长23.72%
业绩增长期
公司处于发展阶段，最新年度总收入10.00M美元
利润高增长
公司净利润处于行业前列，最新年度总收入10.00M美元
估值高估
公司最新PE估值-7.19，处于3年历史高位
机构减仓
最新机构持股65.86M股，环比减少12.29%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值5.55K
分析师目标
根据
20
位分析师
买入
评级
53.500
目标均价
+292.52%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Janux Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Janux Therapeutics Inc简介
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
公司代码JANX
公司Janux Therapeutics Inc
CEOCampbell (David)
网址https://www.januxrx.com/
相关品种
